Current Report Filing (8-k)
September 01 2016 - 6:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 31, 2016
GenVec, Inc.
(Exact name of
registrant as specified in its charter)
Delaware
(state
or other jurisdiction of
incorporation)
|
000-24469
(Commission
File
Number)
|
23-2705690
(I.R.S.
Employer
Identification
No.)
|
|
|
|
910
Clopper Road
Suite
220N
Gaithersburg,
Maryland
|
20878
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
(240) 632-0740
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 7 – Regulation FD
Item 7.01. Regulation FD Disclosure.
On August 31, 2016, press reports disclosed
that Novartis is planning to eliminate its internal unit dedicated to cell and gene therapy and redeploy most of the affected employees.
Novartis is developing CGF166, GenVec's lead product candidate for hearing loss, under a Research Collaboration and License Agreement
between the two parties. Novartis has informed GenVec that it remains engaged on the CGF166 program and that Novartis's internal
changes are not expected or intended to reduce its support for the program.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
GENVEC, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Douglas J. Swirsky
|
|
|
|
Douglas J. Swirsky
|
|
|
|
President, Chief Executive Officer and Corporate
Secretary
|
Dated: September 1, 2016
Genvec, Inc. (NASDAQ:GNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genvec, Inc. (NASDAQ:GNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024